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Incentive spirometryAbstract Background: Incidence of gastric fundal varices is about 16–70% of patients with portal
hypertension. It causes upper gastrointestinal bleeding in about 10–15% of cases. There are
different methods used for the management of gastric varices. Endoscopic injection of N-Butyl-
Cyanoacrylate (NBCA) is considered to be the choice for control of active bleeding from gastric
varices. Pulmonary complications of sclerotherapy are common and varying from minor complica-
tions to severe complications as pleural effusion, lung collapse, consolidation, adult respiratory
distress syndrome and pulmonary embolism.
Aim: To evaluate pulmonary functions after endoscopic sclerotherapy of gastric fundal varices
by N-Butyl-Cyanoacrylate and the effect of incentive spirometry (IS) on post sclerotherapy
pulmonary functions.
Methods: Sixty patients with liver cirrhosis and portal hypertension were included in the study.
All patients were subjected to full history and careful clinical examination, upper GI endoscopy,
Child-Turcotte-Pugh classiﬁcation, chest X-ray and high resolution CT chest with contrast on
the day just before endoscopy and within 48 h post procedure, ABGs and spirometry for FVC
(%pred), FEV1 (%pred), FEV1/FVC%, FEF 25–75 (%pred) and PEFR (%pred) 6 h before and
2 days after GI endoscopy. Patients were divided into two groups according to the result of upper
GI endoscopy: Group 1: included 30 patients with liver cirrhosis and portal hypertension, with
upper GI endoscopy revealed gastric fundal varices and injection sclerotherapy with NBCA was
done; Group 2: included 30 patients with liver cirrhosis and portal hypertension with upper GI
endoscopy showed no gastric fundal varices or non risky, small sized fundal varices which were, forced
ory ﬂow
dioxide
846 J.A. Shawky et al.not injected. G1 was further divided randomly into 2 subgroups (G1a and G1b) with measurement
of ABGs and spirometry parameters after application of incentive spirometry.
Results: 16.67% and 6.67% of patients in group (1) developed pleural effusion and atelectatic
bands of the lung respectively after sclerotherapy. There was a statistically signiﬁcant decrease in
PaO2, FVC (%pred), FEV1 (%pred) and FEF 25–75 (%pred) in group (1) after sclerotherapy from
80.12 ± 12.91, 98.25 ± 10.74, 90.86 ± 4.21 and 82.12 ± 29.21 to 71.96 ± 19.89, 82.11 ± 9.61,
75.65 ± 3.15 and 50.03 ± 20.11 respectively. The deteriorated parameters in G1a was improved
after the application of incentive spirometry for 2 days regarding PaO2, SaO2, FVC, FEV1 and
FEF 25–75 from 69.91 ± 17.93, 90.01 ± 3.84, 80.27 ± 8.71, 75.12 ± 1.96, 52.14 ± 19.24 to
83.23 ± 19.07, 97.85 ± 5.72, 88.97 ± 9.94, 87.01 ± 1.03, 72.91 ± 18.13, respectively, on the other
hand, there was a non signiﬁcant statistical difference in all parameters of G1b. Also, there was a
signiﬁcant correlation between numbers of NBCA ampoules used for sclerotherapy and decrease in
Post procedure PaO2, Post FEV1 (%pred), Post FVC (%pred) and Post FEF 25–75 (%pred).
Conclusions: NBCA injection of gastric fundal varices was associated with signiﬁcant, reversible
deterioration in some pulmonary functions, atelectasis and minimal pleural effusion with signiﬁcant
rapid improvement if incentive spirometry is used.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Incidence of gastric fundal varices (GV) is 16–70% in patients
with liver cirrhosis and portal hypertension, and is responsible
for 10–15% of variceal bleeding [1].
There are many methods for the management of gastric
varices and these methods differ from primary to secondary
prevention, and differ between institutions [2].
Injection sclerotherapy with N-Butyl Cyanoacrylate
(NBCA) is thought to be the treatment of choice for active
bleeding from gastric varices and prevention of rebleeding
[3–5].
Gastric varices are less frequent than esophageal varices,
but gastric varices are more dangerous and have higher
mortality rate 60% [6]. Gastric varices have high incidence
of rebleeding (34–89%) [7] and pulmonary complications of
sclerotherapy are common and ranging from minor asymp-
tomatic changes, to serious complications as aspiration,
broncho-pneumonia, pleural effusions, lung collapse, adult
respiratory distress syndrome and pulmonary embolism [8,9].
The aim of this study was to evaluate some pulmonary
functions after endoscopic sclerotherapy of gastric fundal
varices by NBCA injection and the effect of incentive spirom-
etry (IS) on post sclerotherapy pulmonary functions.
Patients and methods
This study was conducted at Tropical Medicine and Chest
Departments, Zagazig University Hospitals, between January
2014 and September 2015.
Sixty patients with liver cirrhosis and portal hypertension
were included in this study, all patients were subjected to upper
GIT endoscopy and were divided into two groups according to
endoscopy ﬁnding:
Group (1): 30 patients with liver cirrhosis and portal
hypertension and upper GIT endoscopy reveals fundal varix
was injected with N-Butyl-Cyanoacrylate.
Group (2): 30 patients with liver cirrhosis and portal
hypertension and upper GIT endoscopy was without injectionsclerotherapy as there were no varices or small non-risky
fundal varices.
Exclusion criteria:
– Patients with hepatocellular carcinoma.
– Patients with non cirrhotic portal hypertension.
– Patients with cardiac or chronic lung diseases.
– Smokers and alcoholic.
All patients were subjected to the following:
 Full history and thorough clinical examinations.
 Complete blood count.
 Liver function tests
 Kidney function tests.
 Serum alpha-fetoprotein.
 Child-Turcotte-Pugh (CTP) classiﬁcation for each patient
according to serum albumin, serum bilirubin, ascites,
history of encephalopathy and prothrombin time.
 Abdominal ultrasound.
 Upper GIT endoscopy, using Pentax Videoscopy.
 Chest X-ray and high resolution CT chest with contrast on
the day just before endoscopy and within 48 h post
procedure in both groups [10].
 ABGs (RAPIDLab348EX) and spirometry (winspiroPRO5.0.0)
were done 6 h before and 2 days after GIT endoscopy in
both groups [11–13].
G1 was further divided randomly into 2 subgroups :
Group 1a (G1a ) and group 1b (G1b) as follow:
G1a: Subjected to IS (three-ball, ﬂow-measuring device
Plasti-med THREE BALL) for 2 days [14] then re-
measurement of the same parameters. IS (sustained maximal
inspiration), the patient inhales at a predetermined ﬂow and
sustains the inﬂation for at least 5 s. The patient is instructed
to hold the spirometer in an upright position, exhale normally,
and then place the lips tightly around the mouthpiece. The
next step is a slow inhalation to raise the ball (ﬂow-oriented)
in the chamber to the set target. At maximum inhalation, the
mouthpiece is removed, followed by a breath-hold and normal
Pleuropulmonary complications after endoscopic sclerotherapy of gastric fundal varices 847exhalation. The effects of 15 min (q2h) while awake of IS is
evaluated [15,14].
G1b: Non incentive spirometry (IS) group (control group)
who received orientation only about the cough technique, early
mobilization and deep breathing exercises (see Table 5).
Both groups were treated according to the conventional
protocol after upper GIT endoscopy (see Table 2).
Results
Table 1 shows that the group 1 included 19 males and 11
females with mean age 50.2 + 4.3 years, and according toTable 1 Demographic data, base line ABGs and spirometry
parameters in both groups.
Group 1 (n= 30) Group 2 (n= 30) P
Age (years) Mean ± SD Mean ± SD >0.05
50.2 ± 4.3 52.3 ± 3.4
Sex n % n % >0.05
Male 19 63.33 17 56.66
Female 11 36.66 13 43.33
Mean ± SD Mean ± SD >0.05
pH 7.41 ± 0.03 7.40 ± 0.02 >0.05
PaO2 (mmHg) 80.12 ± 12.91 83.38 ± 13.25 >0.05
SaO2 (%) 93.41 ± 2.11 91.81 ± 3.21 >0.05
PaCO2 (mmHg) 36.62 ± 3.97 35.91 ± 3.19 >0.05
HCO3 (mEq/L) 21.09 ± 1.98 20.18 ± 2.01 >0.05
FVC (%pred) 98.25 ± 10.74 97.98 ± 11.87 >0.05
FEV1 (%pred) 90.86 ± 4.21 89.90 ± 5.11 >0.05
FEV1/FVC% 85.62 ± 5.91 86.91 ± 6.01 >0.05
FEF 25–75 (%pred) 94.12 ± 29.21 93.22 ± 28.33 >0.05
PEFR (%pred) 80.75 ± 14.99 82.56 ± 21.14 >0.05
Table 2 Child classiﬁcation in both groups.
Groups P
Group 1 (n= 30) Group 2 (n= 30)
No % No %
Child A 12 40 10 33.33 >0.05
B 18 60 20 66.67
Table 3 Endoscopic ﬁndings in both groups.
Endoscopic ﬁndings Group 1 Group 2
No (n= 30) % No (n= 30) %
Esophageal varices
Grade I 3 10 2 6.67
Grade II 5 16.67 6 20
Grade III 12 40 12 40
Grade IV 10 33.33 10 33.33
Portal hypertensive gastropathy
Mild 4 13.33 2 6.67
Moderate 19 63.33 18 60
Severe 7 23.33 10 33.33
Fundal varix 30 100 0 0child classiﬁcation: Child A: 12 and Child B: 18 patients, while
group 2 included 17 male and 13 females with mean age
52.3 + 3.4 years and according to child classiﬁcation,
Child A: 10 and Child B: 20 patients, The 2 groups were
matched together regarding demographic data, base line ABGs
and spirometry parameters FVC (%pred) FEV1 (%pred)
FEV1/FVC% FEF 25–75 (%pred) PEFR (%pred) with no
signiﬁcant difference. There was no signiﬁcant difference in
both groups regarding child classiﬁcation (Table 2). Upper GIT
endoscopic ﬁndings in both groups are included in Table 3.
Table 4 shows a statistically signiﬁcant deterioration of
PaO2, FVC (%pred), FEV1 (%pred) and FEF 25–75 (%pred)
from base time before the procedure and at 2 days after the
injection sclerotherapy in G1 only, while all other parameters
showed non signiﬁcant deterioration.
The improvement in G1a after application of IS was
signiﬁcant regarding PaO2, SaO2, FVC, FEV1 FEF 25–75
but the improvement in FEV1/FVC and PEFR was non signif-
icant, on the other hand, there was non signiﬁcant statistical
difference in all parameters of G1b (non IS group) as shown
in (Table 5).
Pleural effusion and atelectatic bands of lung developed
after sclerotherapy of Group 1 patients in 16.67% and
6.67% respectively (Table 6).
There was a signiﬁcant correlation between each of NBCA
amount (number of used ampoules), age and CTP score of
Group 1 patients and the decrease in Post PaO2, post FEV1
(%pred), Post FVC (%pred) and Post FEF 25–75 (%pred)
as shown in Table 7.
Discussion
In this study endoscopic injection of fundal varix was done
with NBCA without lipidol for primary prophylaxis of gastric
variceal bleeding in Group 1 patient, which cause a rapid
polymerization with a lower risk for distant glue embolization,
this is similar to the study done by Franco et al. [16] who
concluded that endoscopic injection with NBCA undiluted
plus method cyloxy sulfolane may be safe and effective for
primary prophylaxis of gastric variceal bleeding.
The premedication and passage of an endoscopy contribute
to incidence of respiratory dysfunction through hypoxemia
and aspiration pneumonitis. So incidence of impaired respira-
tory functions in patients receiving injection sclerotherapy
should be compared with that in patients undergoing endo-
scopy without injection [10].
The risk for aspiration pneumonia was low in this study as
there was no active bleeding, hepatic encephalopathy or excess
sedation which are contributing factors for incidence of aspira-
tion pneumonia as listed by Krige et al. [10].
In this study, there was a signiﬁcant decrease of PaO2 and
some spirometry parameters 6 h before endoscopy and 2 days
after in Group 1 patients unlike Group 2 patients which
showed no signiﬁcant difference, these ﬁndings are matched
with those of the study done by Sherif et al. [13], on the other
hand, [11] found no signiﬁcant change in PaO2 and matched
with the present study regarding the rest of ABGs parameters
(pH, PaCO2, HCO3, and SaO2 did not change).
The results of spirometry in the current study showed
statistically signiﬁcant deterioration in G1 regarding FVC,
FEV1 and FEF 25–75 while FEV1/FVC%, PEFR showed
Table 4 ABGs and spirometry parameters in both groups pre- and post-procedure.
Group 1 (n= 30) P Group 2 (n= 30) P
Pre G1 Post G1 Pre G2 Post G2
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
pH 7.41 ± 0.03 7.40 ± 0.01 >0.05 7.40 ± 0.02 7.39 ± 0.07 >0.05
PaO2 80.12 ± 12.91 71.96 ± 19.89 <0.05 83.38 ± 13.25 79.13 ± 12.18 >0.05
SaO2 93.41 ± 2.11 90.91 ± 2.95 >0.05 91.81 ± 3.21 90.11 ± 11.12 >0.05
PaCO2 36.62 ± 3.97 37.44 ± 2.98 >0.05 35.91 ± 3.19 36.01 ± 3.09 >0.05
HCO3 21.09 ± 1.98 21.07 ± 1.87 >0.05 20.18 ± 2.01 20.12 ± 1.96 >0.05
FVC (%pred) 98.25 ± 10.74 82.11 ± 9.61 <0.05 97.98 ± 11.87 94.98 ± 13.91 >0.05
FEV1 (%pred) 90.86 ± 4.21 75.65 ± 3.15 <0.05 89.90 ± 5.11 87.25 ± 4.95 >0.05
FEV1/FVC% 85.62 ± 5.91 83.92 ± 7.89 >0.05 86.91 ± 6.01 86.59 ± 6.85 >0.05
FEF2 5–75 (%pred) 82.12 ± 29.21 50.03 ± 20.11 <0.05 80.22 ± 28.33 78.41 ± 24.21 >0.05
PEFR (%pred) 80.75 ± 14.99 79.25 ± 12.35 >0.05 82.56 ± 21.14 81.54 ± 19.96 >0.05
Table 5 ABGs and spirometry parameters after application of incentive spirometry (IS) on 15 patients for 2 days after division of G1
into 2 groups (G1a and G1b) randomly.
Post sclerotherapy parameters for G1 Incentive spirometry group (G1a)
n= 15
P Non incentive spirometry group (G1b)
n= 15
P
Pre IS G1a Post IS G1a Pre orientation G1b Post orientation G1b
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
pH 7.39 ± 0.07 7.38 ± 0.01 >0.05 7.41 ± 0.01 7.39 ± 0.06
PaO2 69.91 ± 17.93 83.23 ± 19.07 <0.05 68.88 ± 15.01 70.91 ± 14.07 >0.05
SaO2 90.01 ± 3.84 97.85 ± 5.72 <0.05 90.09 ± 2.99 91.54 ± 3.09 >0.05
PaCO2 39.21 ± 4.24 38.11 ± 1.91 >0.05 40.09 ± 3.18 39.12 ± 3.18 >0.05
HCO3 19.91 ± 3.09 19.98 ± 3.01 >0.05 21.09 ± 2.79 20.81 ± 2.61 >0.05
FVC 80.27 ± 8.71 88.97 ± 9.94 <0.05 79.77 ± 7.95 81.03 ± 6.74 >0.05
FEV1 75.12 ± 1.96 87.01 ± 1.03 <0.05 75.91 ± 2.01 77.86 ± 1.21 >0.05
FEV1/FVC 87.43 ± 9.03 90.12 ± 8.01 >0.05 91.01 ± 8.09 93.11 ± 7.91 >0.05
FEF 25–75 52.14 ± 19.24 72.91 ± 18.13 <0.05 51.07 ± 18.71 54.14 ± 17.95 >0.05
PEFR 79.25 ± 12.35 81.59 ± 13.09 >0.05 80.09 ± 11.29 81.01 ± 11.29 >0.05
Table 6 CT chest before and after the procedure in both
groups.





No % No %
Pleural eﬀusion pre procedure 0 0 0 0 –
Pleural eﬀusion post procedure 5 16.67 0 0 <0.05
Lung parenchyma (atelectatic
bands before)
0 0 0 0 –
Lung parenchyma (atelectatic
bands after)
2 6.67 0 0 >0.05
Table 7 Correlation between age, CTP score and number of











r 0.962 0.948 0.878 0.900
P <0.005 <0.005 <0.001 <0.001
No 30 30 30 30
CTP score
r 0.830 0.942 0.844 0.858
P <0.001 <0.001 <0.001 <0.005
No 30 80 30 30
NBCA ampoules N
r 0.935 0.874 0.751 0.895
P <0.005 <0.001 <0.001 <0.001
No 30 30 30 30
848 J.A. Shawky et al.non signiﬁcant deterioration and these results are matched
with the comparative study between esophageal variceal
sclerotherapy (EVS) and diagnostic esophagogastroscopy by
Samuels et al. [17], where a restrictive pattern was noted only
after EVS, not after the latter. And also, in agreement with [11]
who found a signiﬁcant decrease in FEV1 and FVC of 7.21%
and by 9.02%, respectively, after EVS the change in the
FEV1/FVC ratio was not signiﬁcant. Moreover, [12] found a
highly signiﬁcant decrease in VC, FVC, FEV1 and PEF, anda signiﬁcant decrease of FEF50, PaO2, and O2 saturation
(SaO2) 2 days after the injection sclerotherapy when compared
with esophageal band ligation (EBL) and also a highly signif-
icant decrease of VC, FVC, FEV1, paO2 and SaO2in the EST
group when compared before and 2 days after the procedure,
Pleuropulmonary complications after endoscopic sclerotherapy of gastric fundal varices 849this indicates that a restrictive ventilatory defect occurred after
injection sclerotherapy. The spirometric data in the most
recent study done by Sherif et al. [13] also agreed with our
study where it revealed a restrictive ventilatory defect early
after EVS which did not improve after 3 weeks. This restrictive
ventilatory defect in pulmonary function could be explained by
sclerosant embolization through para esophageal and azygous
vein to the lung resulting in areas of alveolar exudate, atelecta-
sis, consolidation and increase in lung stiffness as evident by
Samuels et al. [17], Seewald et al. [18], Krige et al. [10], Rezk
and El-Maleky [12] who tried to explain their results by an
incomplete resolution of embolism of a sclerosant agent to
pulmonary vasculature or interstitial pneumonitis from the
sclerosant agent.
In the current study there were 16.67% and 6.67% of
patients of Group 1 who developed pleural effusion and atelec-
tatic bands of lung after sclerotherapy respectively. These
results were in concordance with results of the study by Sethy
et al. [11], although he included 26 patients with esophageal
varices subjected to injection by alcohol. However, in the
present study, ﬁve patients (16.5%) only developed mild right
sided pleural effusion and 2 patients showed atelectatic bands.
This is less than the incidence in study by Bacon et al. [19]
(48%), Zeller et al. [20] (27) and Sethy et al. [11] (23.08%)
who used oil based sclerosant. Most of these effusions were
asymptomatic and resolved spontaneously indicating that
undiluted cyanoacrylate is an effective procedure for primary
prophylaxis of gastric varices [21,22,12] and in the recent study
of [13] they found pleural effusion in (24%), and atelectasis
in (16.5%).
The role of IS for 2 days post endoscopic sclerotherapy is
evaluated in this study and showed signiﬁcant improvement
regarding PaO2, SaO2, FVC, FEV1 FEF 25–75 but the
improvement in FEV1/FVC and PEFR was non signiﬁcant
and this is in harmony with other studies evaluating the value
of IS similar to that of [15,23,24] who also explained this
improvement in pulmonary functions by the fact that maximal
sustained inspiration may enable increased retractive forces by
the transmural pressure to reopen collapsed alveoli, thus
leading to an increased recruitment of the nonventilated.
Moreover, [25] indicated that the IS was better in increasing
respiratory muscle strength. On the other hand, other studies
similar to that of [26,27] indicated that IS did not improve
PaO2, VC and FEV1.
In this study, there was more deterioration in PaO2 and
some spirometry parameters with increasing numbers of
NBCA ampoules and CTP score. The latter may be explained
by the increasing incidence of portosystemic shunting in the
decompensated cirrhosis [28].
Conclusion
NBCA injection of gastric varices is associated with a signiﬁ-
cant decrease in PaO2 and restrictive ventilatory function
due to the pleuro-pulmonary abnormalities, however, they
are transient and self limited, moreover, incentive spirometry
is recommended in post endoscopic injection of fundal varix,
as a simple, easy and cheap tool, to hasten the improvement
of the impaired pulmonary functions and accordingly, undi-
luted NBCA is safe in primary prophylaxis of gastric varices.Conflict of interest
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